2020 Annual Global Meeting: Virtual-Plenary III: Oral Abstract Presentations

Video Transcription

Video Summary

In this plenary session, there were two presentations summarized. The first presentation was on a phase 2 study of an oncolytic vaccine, Primed Immunochemotherapy, in heavily pre-treated ovarian cancer patients. The study used an intraperitoneal oncolytic vaccinia virus, Albevec, followed by intravenous platinum-based doublet chemotherapy. The results showed a promising objective response rate, progression-free survival, and disease control rate, with a low rate of side effects. The second presentation focused on a study comparing an individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib in newly diagnosed advanced ovarian cancer patients. The ISD regimen was based on body weight and platelet count. The study found that the ISD regimen had comparable efficacy to the FSD regimen, with improved tolerability and reduced rates of hematologic adverse events. The study also showed no difference in quality of life between the two regimens. Overall, both presentations showed promising results and provide insight into improving treatment outcomes and reducing side effects for ovarian cancer patients.

Keywords

plenary session

presentations

phase 2 study

oncolytic vaccine

ovarian cancer patients

intraperitoneal oncolytic vaccinia virus

objective response rate

tolerability

treatment outcomes